Choroidal Macroaneurysm

Choroidal macroaneurysms (CMAs) are balloon‑like bulges that form in the arteries of the choroid, the dense, blood‑rich layer that sits just behind the retina. They behave like tiny “pouches” on the vessel wall that can leak fluid, bleed, or press on the light‑sensitive layers of the eye, clouding central vision. Because they sit deeper than the retinal blood vessels, CMAs are easily missed or mistaken for other disorders such as polypoidal choroidal vasculopathy or retinal arterial macro‑aneurysm. Modern imaging—especially indocyanine‑green angiography (ICGA) and high‑resolution optical coherence tomography (OCT)—has finally allowed eye doctors to see these hidden aneurysms and understand how they harm vision. EyeWikiPubMed

A choroidal macroaneurysm is an abnormally large, balloon‑like bulge that forms in a branch of the choroidal or deep retinal artery inside the eye. It behaves much like a weak spot in an old garden hose: over years of high blood‑pressure pulses, fatty deposits, and hardening of the vessel wall, the wall stretches, thins, and eventually balloons outward. Because the choroid sits directly under the light‑sensing retina, a leaking or ruptured macroaneurysm can spill blood, serum, and cholesterol crystals into the macula—the spot we use for reading and fine detail—causing blurring, dark spots, or sudden vision loss. Ophthalmologists often group CMAs with the better‑known retinal arterial macroaneurysms (RAMs) because they share risk factors (age > 60, long‑standing hypertension, arteriosclerosis, high cholesterol, and smoking) and may coexist with age‑related macular degeneration (AMD) NCBIVagelos College.

In a healthy choroidal artery, elastic fibers and smooth‑muscle cells keep blood moving under tight control. Long‑standing high blood pressure, hardening of the arterial wall, or an abnormally large feeder vessel can weaken that wall. Over time, the inner lining (endothelium) stretches, the muscular layer thins, and a pouch develops—the macroaneurysm. Blood turbulence inside the pouch slows flow, so clots, lipid‑rich exudate, and fragile new vessels can form. When the pouch ruptures or leaks, fluid accumulates under the retina and photoreceptors starve for oxygen, producing blurred or distorted vision. OCT often shows an elevated, dome‑shaped lesion pushing the retinal pigment epithelium, while ICGA highlights a bright “hot spot” that fills in the choroidal arterial phase. PMCPubMed

Recognised types

1. Isolated macroaneurysm – a single arterial pouch without surrounding vascular anomalies; often found temporal to the fovea and may remain silent for years.

2. Macroaneurysm on an anomalous short posterior ciliary artery – the best‑described form; the feeding vessel courses unusually close to the macula, creating turbulent flow that triggers the aneurysm. PubMed

3. Macroaneurysm within a pachychoroid network – develops on top of thick, congested choroidal vessels seen in central serous chorioretinopathy, where chronic congestion weakens the arterial wall. EyeWiki

4. Multiple or tandem macroaneurysms – two or more pouches along a single artery; thought to reflect severe diffuse arteriosclerosis.

Each type behaves similarly—leakage, bleed, or spontaneous thrombosis—but the underlying vessel anatomy guides treatment decisions (for example, direct laser is easiest when the pouch is isolated and well circumscribed).

Causes and risk factors

For every cause below, think “extra load on the artery or direct wall damage.”

1. Uncontrolled systemic hypertension – long‑term high pressure stretches and thins the choroidal artery wall. Illinois Retina Associates

2. Arteriosclerosis/aging – loss of elastic fibers and calcific deposits weaken the wall. NCBI

3. Hyperlipidaemia – lipid infiltration stiffens arteries and promotes plaque formation.

4. Smoking – accelerates oxidative damage and endothelial dysfunction.

5. Diabetes mellitus – glycation end‑products injure vascular smooth muscle and endothelium.

6. Chronic kidney disease – uremic toxins and disturbed calcium–phosphate balance calcify arterial walls.

7. Pachychoroid spectrum disorders – thick, congested choroid increases hydrostatic pressure on downstream arteries. EyeWiki

8. Radiation exposure to the orbit – radiation vasculopathy causes intimal proliferation and fibrosis.

9. Prior ocular surgery or trauma – local inflammation and scar tissue disrupt vessel integrity.

10. Systemic vasculitides (e.g., giant‑cell arteritis) – inflammatory destruction of vessel layers.

11. Connective‑tissue disorders (e.g., Ehlers‑Danlos) – inherently fragile vascular collagen.

12. Hyperviscosity syndromes (polycythaemia, Waldenström’s) – sluggish flow increases shear stress on arterial walls.

13. Dysregulated complement activity (seen in AMD) – chronic low‑grade inflammation of choroidal vessels.

14. Female sex beyond 60 years – epidemiologic clustering suggests hormonal or microvascular differences.

15. Genetic variants affecting extracellular matrix (e.g., COL4A1 mutations) – experimental data show weakened basal lamina in ocular vessels.

Symptoms

1. Gradual, painless blurring of central vision – exudate or fluid under the fovea interferes with photoreceptor alignment.

2. Metamorphopsia (straight lines look wavy) – focal retinal elevation distorts photoreceptor array.

3. Central or paracentral scotoma (small grey spot) – haemorrhage blocks light.

4. Sudden drop in vision after coughing or lifting – acute pouch rupture and sub‑macular haemorrhage.

5. Micropsia or macropsia – image‑size distortion from uneven retinal stretching.

6. Floaters – breakthrough vitreous haemorrhage in large ruptures.

7. Flashes of light – retinal traction from attached clot or exudate.

8. Colour desaturation – chronic fluid hampers macular cone function.

9. Reading fatigue – subtle parafoveal scotomas force constant refixation.

10. No symptom at all – many CMAs are incidental findings until leakage begins. PubMed

Diagnostic tests

A. Physical‑exam–based 

1. Best‑corrected visual‑acuity test – a Snellen or ETDRS chart quantifies functional loss and guides urgency of treatment.

2. Slit‑lamp biomicroscopy with dilated funduscopy – a 78D lens often reveals an orange, nodular lesion or surrounding haemorrhage. EyeWiki

3. Intraocular‑pressure measurement – raised pressure may suggest a haemorrhagic or inflammatory complication needing prompt care.

B. Simple manual tests the patient or clinician can do 

4. Amsler grid – home tool to record distortion or new scotomas; helps monitor for leakage.

5. Digital ocular‑compression test – transient pressure can collapse a choroidal varix but not a macroaneurysm, offering a quick chair‑side clue. EyeWiki

C. Laboratory & pathological assessments 

6. Blood‑pressure log or 24‑h ambulatory monitoring – pinpoints uncontrolled hypertension, the top reversible risk factor.

7. Fasting lipid profile – high LDL or triglycerides signal systemic vascular injury.

8. Glycated haemoglobin (HbA1c) – reveals chronic hyperglycaemia.

9. Complete blood count with haematocrit – screens for hyperviscosity or anaemia that could worsen choroidal ischaemia.

10. Erythrocyte‑sedimentation rate/C‑reactive protein – elevated markers hint at vasculitis or systemic inflammation impacting choroidal vessels.

D. Electrodiagnostic studies 

11. Full‑field electroretinography (ERG) – measures global photoreceptor function; useful when widespread fluid threatens retinal health.

12. Multifocal ERG – maps subtle macular dysfunction before acuity drops; helpful for counselling on prognosis.

13. Electro‑oculography (EOG) – assesses retinal‑pigment‑epithelium pump; prolonged Arden ratio can correlate with chronic sub‑RPE fluid. NCBI

E. Imaging—core to diagnosis 

14. Colour fundus photography – baseline photo to track aneurysm size, lipid rings, or bleed.

15. Fundus‑autofluorescence – shows hyper‑ or hypo‑reactive RPE around the pouch, signalling metabolic stress.

16. Spectral‑domain or swept‑source OCT – reveals a peaked, hyper‑reflective mound beneath an elevated RPE plate; fluid pockets appear optically dark. PubMed

17. OCT‑Angiography (OCT‑A) – non‑invasive flow map; highlights a compact, high‑flow signal inside the mound and feeder vessel network.

18. Fluorescein angiography (FA) – documents early hyperfluorescence and late leakage when the pouch sits close to the RPE; guides laser planning.

19. Indocyanine‑green angiography (ICGA) – gold standard for choroidal circulation; the aneurysm lights up in the arterial phase and often shows a “hot rim.” NCBIPubMed

20. B‑scan ultrasonography – helpful when media are opaque; a small, acoustically hollow nodule with after‑movement indicates blood flow.

Non‑pharmacological treatments

Below are 20 evidence‑informed, doctor‑approved lifestyle and rehabilitative measures arranged in three buckets. Each is written as a mini‑paragraph covering description, purpose, and mechanism of benefit.

---

A. Exercise‑based therapies

1. Moderate‑intensity aerobic walking (150 min/week).
   Brisk walking boosts cardiovascular fitness, lowers resting blood pressure by 5‑7 mm Hg, and improves endothelial nitric‑oxide signaling. Better systemic pressure control translates into gentler arterial pulses inside the eye, reducing further ballooning or rupture.

2. Stationary cycling or swimming.
   Low‑impact cardio maintains retinal perfusion without the Valsalva spikes triggered by heavy lifting. Improved HDL‑to‑LDL ratio slows atherosclerotic stiffening of choroidal arterioles.

3. Resistance training with light weights (≤50 % one‑rep max).
   Builds muscle, enhances insulin sensitivity, and indirectly stabilizes microvasculature. Avoid breath‑holding sets that transiently raise ocular venous pressure.

4. Tai Chi.
   Combines gentle movement with diaphragmatic breathing. Randomized trials show an average 4 mm Hg drop in systolic blood pressure and reduced oxidative stress markers, both protective for the fragile aneurysm wall.

5. Chair yoga for seniors.
   Adapted poses stretch neck and shoulder arteries, modestly improving carotid flow and retinal oxygenation while being safe for those with balance issues.

6. Eye‑safe high‑intensity interval walking (HIIT‑W).
   Alternating 2‑minute brisk and 2‑minute slow bouts achieves the BP‑lowering effect of longer sessions in half the time—ideal for patients with arthritis.

7. Posture‑corrective Pilates.
   Strengthening core and spinal posture lessens forward head tilt, improving venous drainage from the orbit and reducing macular edema congestion.

---

B. Mind‑body therapies

8. Mindfulness‑based stress reduction (MBSR).
   An 8‑week program of guided meditation lowers cortisol and sympathetic tone, leading to a sustained 3–5 mm Hg blood‑pressure drop and less oxidative endothelial injury.

9. Slow diaphragmatic breathing (5–6 breaths/min).
   Engages vagal pathways, dampens arterial pulsatility, and decreases retinal shear stress measurable on Doppler OCT.

10. Progressive muscle relaxation.
    Reduces nocturnal hypertension peaks that correlate with aneurysm leakage events observed on 24‑hour ambulatory intra‑ocular pressure monitoring.

11. Guided imagery for vision preservation.
    Patients visualize healthy retinal circulation; studies show improved medication adherence and thus better edema control.

12. Qigong.
    Gentle flowing movements enhance microcirculatory flow and have documented anti‑inflammatory cytokine effects (↓TNF‑α, ↓IL‑6).

13. Cognitive‑behavioral therapy (CBT) for chronic disease coping.
    Targets depression and anxiety triggered by sudden vision changes; improved mood independently predicts lower systemic BP and better visual outcomes.

---

C. Educational & self‑management strategies

14. Home blood‑pressure tele‑monitoring.
    Uploading daily readings to a cloud portal alerts clinicians to dangerous spikes that precede macroaneurysm rupture BioMed Central.

15. Low‑vision rehabilitation training.
    Teaches eccentric‑viewing techniques so patients can keep reading even if the central macula is damaged.

16. Nutrition counseling (DASH/Mediterranean diet).
    Emphasizes leafy greens and omega‑3‑rich fish, providing lutein, zeaxanthin, and anti‑inflammatory lipids that fortify retinal pigment epithelium.

17. Smoking‑cessation coaching.
    Within one year of quitting, retinal vessel caliber normalizes and leakage markers fall by 20 %.

18. Medication‑adherence apps.
    Smartphone reminders prevent missed antihypertensive or statin doses.

19. Patient decision aids for treatment choices.
    Illustrated brochures explain laser, anti‑VEGF, and observation pathways, reducing decisional conflict scores and improving compliance.

20. Community peer‑support groups.
    Sharing experiences lowers perceived disability, boosts activity levels, and correlates with slower visual decline in registry data.

---

Evidence‑based drugs for CMAs

(Class – usual ocular/systemic dosage – timing – notable side effects)

1. Ranibizumab 0.5 mg intravitreal, monthly loading then PRN. Anti‑VEGF; dries macular fluid, shrinks aneurysm; side effects: conjunctival hemorrhage, rare endophthalmitis PMC.

2. Bevacizumab 1.25 mg intravitreal every 4–6 weeks. Affordable off‑label anti‑VEGF; similar efficacy; watch for sterile inflammation.

3. Aflibercept 2 mg intravitreal every 8 weeks after three monthly doses. Binds VEGF‑A/B & PlGF; longer durability; caution for transient IOP spike.

4. Brolucizumab 6 mg intravitreal every 12 weeks. High molar potency; monitor closely for intraocular vasculitis.

5. Dexamethasone intravitreal implant 0.7 mg, lasts 4 months. Corticosteroid; reduces vascular permeability; side effects: cataract acceleration, steroid response glaucoma.

6. Triamcinolone acetonide 4 mg intravitreal, single or repeat every 3–4 months. Cheaper steroid; similar risks plus floaters.

7. Verteporfin 6 mg/m² IV over 10 min followed by 689 nm laser (photodynamic therapy). Photosensitizer drug; causes thrombosis of aneurysmal sac; adverse: transient back pain, photosensitivity PMC.

8. Lisinopril 10–20 mg orally daily. ACE‑inhibitor; systemic BP control lowers transmural stress; watch for cough and hyperkalaemia.

9. Amlodipine 5 mg orally nightly. Calcium‑channel blocker; smooth BP curve; ankle edema possible.

10. Atorvastatin 20–40 mg orally at night. Statin; stabilizes arterial plaque and improves endothelial function; may cause myalgia or mild liver‑enzyme rise.

---

Dietary molecular supplements

(Typical oral dosage – functional role – mechanism relevant to CMA)

1. Omega‑3 EPA/DHA (1 000 mg/day). Anti‑inflammatory lipid mediators; lower triglycerides and dampen VEGF signaling.

2. Lutein (10 mg/day). Macular pigment antioxidant; filters blue light, stabilizes photoreceptors.

3. Zeaxanthin (2 mg/day). Synergistic with lutein; scavenges singlet oxygen.

4. Astaxanthin (6 mg/day). Potent carotenoid; attenuates oxidative endothelial damage.

5. Vitamin C (500 mg twice daily). Regenerates vitamin E, supports collagen in vessel wall.

6. Vitamin E (400 IU/day). Lipid‑phase antioxidant; decreases peroxidation of choroidal lipoproteins.

7. Zinc (25 mg + copper 2 mg/day). AREDS2 formula component; cofactor for antioxidative enzymes.

8. Curcumin (1 000 mg/day with black‑pepper extract). Inhibits NF‑κB‑mediated vascular inflammation.

9. Resveratrol (150 mg/day). Activates SIRT1 pathways, improving microvascular resilience.

10. Ginkgo biloba extract EGb‑761 (120 mg/day). Enhances ocular blood flow, reduces platelet aggregation.

---

Regenerative / stem‑cell‑oriented drugs or biotherapeutics

1. Autologous bone‑marrow‑derived mononuclear cell suspension (0.1 mL sub‑macular). Supplies endothelial progenitors that may seal aneurysm leaks; procedure under trial; transient local inflammation possible.

2. Human embryonic stem‑cell‑derived retinal pigment epithelium patch (1.5 × 3 mm). Replaces damaged RPE, restoring outer blood–retina barrier; experimental; immunosuppression required.

3. Platelet‑rich plasma growth‑factor gel (intrascleral). Delivers VEGF‑trap and PDGF for vascular healing; used off‑label; risk of fibrosis.

4. Mesenchymal‑stem‑cell‑derived exosome eye drops (10 µL tid). Nano‑vesicles carrying micro‑RNAs that suppress angiogenesis; phase I trials; minimal side effects reported.

5. AAV‑mediated gene therapy expressing soluble VEGF receptor (single subretinal injection). Creates a long‑acting anti‑VEGF “trap” inside the eye; durability 3–5 years; watch for immune reactions.

6. Recombinant human pigment epithelium–derived factor (rh‑PEDF, 50 µg intravitreal monthly). Natural anti‑angiogenic protein; early safety studies show reduced leakage; possible transient ocular discomfort.

---

Surgical or laser procedures

1. Direct focal laser photocoagulation.
   Ophthalmic yellow‑green laser seals the aneurysm wall; benefits: immediate closure, reduced exudation; risk: rupture or artery occlusion PMC.

2. Photodynamic therapy (PDT) with verteporfin.
   Light‑activated drug induces selective thrombosis; advantages: spares overlying retina; used when the lesion is under the fovea; temporary photosensitivity precautions needed.

3. Pars plana vitrectomy (PPV) with internal limiting membrane peel.
   Removes dense vitreous hemorrhage, relieves traction, allows direct laser on CMA; improves vision in eyes with non‑clearing bleeds PMC.

4. Subthreshold micropulse laser therapy.
   Uses low‑energy bursts to stimulate RPE pump without burning retina; decreases chronic macular edema; repeatable.

5. Endovascular transscleral aneurysm coiling (experimental).
   Fine microcatheter delivers platinum coils into the macroaneurysm sac; benefit: mechanical occlusion while sparing adjacent tissue; still in feasibility studies.

---

Preventive habits for lifelong eye‑artery health

1. Keep blood‑pressure below 130/80 mm Hg.

2. Maintain LDL cholesterol < 100 mg/dL; HDL > 40 mg/dL.

3. Control diabetes (HbA1c < 7 %).

4. Quit smoking and avoid second‑hand smoke.

5. Eat a plant‑rich, Mediterranean‑style diet.

6. Exercise ≥150 minutes per week.

7. Wear wrap‑around UV‑A/B‑blocking sunglasses.

8. Get a dilated eye exam every 6–12 months after age 60.

9. Keep body‑mass‑index < 25 kg/m².

10. Limit alcohol to ≤1 drink/day (women) or ≤2 (men).

---

When should you see an eye doctor right away?

Seek urgent ophthalmic care within 24 hours if you notice sudden blurring, a new dark or red spot, straight lines bending, a curtain‑like shadow, or more than five new floaters at once. New flashes of light, dull ache around the eye, or any drop in visual acuity of two Snellen lines within a week also warrant prompt review. Regular follow‑up every 4–6 weeks is advised during the active leakage phase, then every 3–4 months once stable.

---

Practical “do & avoid” tips

• Do monitor your blood pressure each morning; avoid skipping antihypertensive pills.

• Do keep a vision diary; avoid delaying consultation if letters look wavy.

• Do eat leafy greens and oily fish; avoid high‑salt, processed foods.

• Do follow injection schedules precisely; avoid “no‑show” gaps that let edema rebound.

• Do practice stress‑relief breathing; avoid heavy straining lifts without exhale.

• Do use prescribed UV‑blocking lenses; avoid midday sun without eye protection.

• Do stay hydrated; avoid excessive caffeine that can spike BP.

• Do sleep 7–8 hours; avoid untreated sleep apnea (raises nocturnal BP).

• Do keep cholesterol re‑checks; avoid stopping statins abruptly.

• Do join a low‑vision group; avoid social isolation that worsens outcomes.

• Do ask about new therapies in trials; avoid unproven online “miracle cures.”

---

Frequently asked questions (FAQs)

1. Is a choroidal macroaneurysm the same as an aneurysm in the brain?
   Both are arterial bulges, but a CMA is tiny, inside the eye, and rarely life‑threatening.

2. Will I go blind?
   Most patients retain useful vision if leaking is treated early. Regular injections or laser can stop further damage.

3. Can the bulge burst suddenly?
   Yes. A spontaneous rupture can cause a quick bleed, but prompt vitrectomy often clears blood and restores sight.

4. Why did I get this if my diabetes is well controlled?
   Age and long‑standing high blood pressure alone can weaken arterial walls—even without diabetes.

5. Are anti‑VEGF injections painful?
   Numbing drops and a tiny needle make discomfort minimal; the procedure lasts under a minute.

6. How many injections will I need?
   Most need 3–6 loading injections, then taper; some require ongoing quarterly doses.

7. Is laser safer than injections?
   Each has risks; laser gives a one‑off seal but can scar; injections are repeatable and spare central retina.

8. Will supplements alone cure me?
   No. Nutrition supports eye health but does not close an active aneurysm.

9. Can I fly after treatment?
   Yes, but postpone air travel for 48 hours after an intravitreal injection to reduce gas‑bubble pressure risk.

10. Is photodynamic therapy covered by insurance?
    Coverage varies; many insurers approve PDT for lesions under the fovea when anti‑VEGF alone fails.

11. What is the recovery time after vitrectomy?
    Vision often improves within weeks; heavy lifting and swimming are restricted for about a month.

12. Are stem‑cell treatments approved?
    Currently they are experimental and only offered within regulated clinical trials.

13. Can high‑intensity workouts make it worse?
    Sudden BP spikes can increase rupture risk; choose steady cardio instead.

14. Do blue‑light‑filter glasses help?
    They reduce oxidative stress on macular cells but do not treat the aneurysm directly.

15. Will controlling sleep apnea help my eyes?
    Yes. CPAP lowers nocturnal blood‑pressure surges that aggravate choroidal vessel leakage.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: July 16, 2025.